1. How do the per-nucleotide mutation rates of RNA viruses and DNA viruses compare, and what is the consequence for the preformed mutant spectrum?
A) RNA and DNA viruses mutate at essentially identical rates, so the preformed mutant spectrum is the same size for both.
B) RNA viruses mutate at approximately 10^-4 to 10^-6 substitutions per nucleotide per cycle versus approximately 10^-7 to 10^-8 for DNA viruses such as herpesviruses, giving RNA viruses a larger preformed mutant spectrum.
C) DNA viruses mutate faster than RNA viruses because their larger genomes accumulate more total copying errors per cycle.
D) RNA viruses mutate roughly 100-fold faster than DNA viruses, but both produce mutant spectra too small to contain pre-existing resistant variants.
E) Mutation rate is determined by host cell type rather than by viral polymerase class, so the two virus types cannot be ranked.
ANSWER: B
Rationale:
Option B is correct. RNA viruses replicate with error-prone RNA-dependent RNA polymerases lacking proofreading, producing roughly 10^-4 to 10^-6 substitutions per nucleotide per cycle. DNA viruses such as herpesviruses replicate with higher fidelity at roughly 10^-7 to 10^-8 per nucleotide per cycle, generating a smaller preformed mutant spectrum while still producing resistant variants under sustained selection.
Option A: Option A is incorrect. The two classes differ by several orders of magnitude in mutation rate; their mutant spectra are not equivalent in size.
Option C: Option C is incorrect. DNA viruses mutate more slowly, not faster, and genome size is not the driver — polymerase fidelity is.
Option D: Option D is incorrect. While RNA viruses do mutate far faster, their large mutant spectra readily contain pre-existing resistant variants; the claim that spectra are too small is wrong.
Option E: Option E is incorrect. Mutation rate is governed primarily by viral polymerase fidelity (proofreading vs none), not by host cell type.
2. The K65R (lysine-to-arginine at position 65) mutation in HIV reverse transcriptase has a distinctive selection profile among nucleoside reverse transcriptase inhibitors (NRTIs). Which statement accurately describes it?
A) K65R is selected by zidovudine (ZDV) and confers high-level zidovudine resistance while sparing tenofovir.
B) K65R is a non-nucleoside reverse transcriptase inhibitor binding-pocket mutation unrelated to any NRTI.
C) K65R is an integrase mutation selected by raltegravir and elvitegravir.
D) K65R is selected by tenofovir, abacavir, and didanosine and reduces incorporation of multiple NRTIs, but is not selected by zidovudine — indeed zidovudine suppresses K65R emergence.
E) K65R has no effect on any drug because it lies outside the reverse transcriptase active region.
ANSWER: D
Rationale:
Option D is correct. K65R is selected by tenofovir, abacavir, and didanosine and reduces incorporation of several NRTIs. Importantly, it is not selected by zidovudine; zidovudine actually suppresses K65R emergence, which underlies part of the rationale for zidovudine-containing salvage regimens in specific situations.
Option A: Option A is incorrect. Zidovudine does not select K65R; it suppresses it, and K65R does not confer high-level zidovudine resistance.
Option B: Option B is incorrect. K65R is a reverse transcriptase mutation affecting NRTIs, not a non-nucleoside binding-pocket mutation.
Option C: Option C is incorrect. K65R is a reverse transcriptase NRTI-resistance mutation, not an integrase mutation.
Option E: Option E is incorrect. K65R lies within the reverse transcriptase and meaningfully reduces NRTI incorporation.
3. HIV nucleoside reverse transcriptase inhibitor (NRTI) resistance arises by two mechanistically distinct routes. Which option correctly distinguishes them?
A) Discrimination mutations reduce incorporation of the NRTI triphosphate relative to the natural substrate, whereas excision mutations enhance pyrophosphorolytic removal of an already-incorporated chain-terminator.
B) Discrimination mutations enhance removal of the incorporated chain-terminator, whereas excision mutations block initial incorporation.
C) Both mechanisms act by preventing cellular kinases from phosphorylating the prodrug to its active form.
D) Discrimination mutations act at integrase, whereas excision mutations act at protease.
E) Discrimination and excision are two names for the same single mechanism, distinguished only by which drug selected the mutation.
ANSWER: A
Rationale:
Option A is correct. Discrimination mutations (archetype M184V/I) reduce the enzyme's ability to incorporate the NRTI triphosphate relative to the natural deoxynucleoside triphosphate. Excision mutations (the thymidine analog mutations) instead enhance pyrophosphorolytic removal of the chain-terminating nucleotide after it has been incorporated, restoring chain elongation.
Option B: Option B is incorrect. This reverses the two definitions — excision (not discrimination) enhances removal; discrimination (not excision) impairs incorporation.
Option C: Option C is incorrect. Neither mechanism works by blocking cellular kinase activation of the prodrug; both act within reverse transcriptase.
Option D: Option D is incorrect. Both mechanisms operate within reverse transcriptase, not at integrase or protease.
Option E: Option E is incorrect. They are genuinely distinct biochemical mechanisms, not two labels for one process.
4. How do second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as etravirine and rilpivirine differ from first-generation agents (efavirenz, nevirapine) in resistance behavior?
A) Second-generation NNRTIs require viral thymidine kinase for activation, giving them a higher barrier than first-generation agents.
B) Second-generation NNRTIs are defeated by the same single mutation (K103N) that defeats first-generation agents, with no improvement in barrier.
C) Second-generation NNRTIs have greater binding flexibility within the pocket, allowing retained activity against many single-mutation NNRTI-resistant variants, though activity erodes as multiple NNRTI resistance-associated mutations accumulate.
D) Second-generation NNRTIs bind the integrase active site rather than the reverse transcriptase pocket.
E) Second-generation NNRTIs are nucleoside analogs and therefore share the excision-resistance pathway.
ANSWER: C
Rationale:
Option C is correct. Second-generation NNRTIs (etravirine, rilpivirine) have greater conformational flexibility in the binding pocket, so they retain activity against many viruses carrying a single first-generation NNRTI mutation; their activity is nonetheless eroded by accumulation of multiple NNRTI resistance-associated mutations.
Option A: Option A is incorrect. NNRTIs are not prodrugs requiring viral thymidine kinase; they bind reverse transcriptase directly.
Option B: Option B is incorrect. The point of second-generation NNRTIs is that they are NOT uniformly defeated by single mutations like K103N; their barrier is improved.
Option D: Option D is incorrect. Both NNRTI generations bind the reverse transcriptase hydrophobic pocket, not integrase.
Option E: Option E is incorrect. NNRTIs are non-nucleoside agents and do not act through the excision pathway used by certain NRTIs.
5. Before prescribing the entry inhibitor maraviroc, a specific test must be performed. What is it, and why is it required?
A) Viral load quantification, because maraviroc is effective only when the plasma HIV ribonucleic acid (RNA) exceeds 100,000 copies per milliliter.
B) Host thymidine kinase genotyping, because maraviroc requires that enzyme for activation.
C) UL97 phosphotransferase sequencing, because maraviroc resistance maps to that gene.
D) Phenotypic IC50 testing against zidovudine, because cross-resistance with zidovudine predicts maraviroc failure.
E) Co-receptor tropism testing, because maraviroc inhibits the C-C chemokine receptor type 5 (CCR5) co-receptor and is active only against CCR5-tropic virus; pre-existing CXCR4-tropic or dual/mixed-tropic virus causes treatment failure.
ANSWER: E
Rationale:
Option E is correct. Maraviroc blocks the CCR5 co-receptor and works only against CCR5-tropic HIV. Tropism testing determines whether the patient's virus uses CCR5, CXCR4 (C-X-C chemokine receptor type 4), or both; if CXCR4-tropic or dual/mixed-tropic virus is present, maraviroc will fail, so the test is mandatory before prescribing.
Option A: Option A is incorrect. Maraviroc selection depends on co-receptor tropism, not on a viral load threshold.
Option B: Option B is incorrect. Maraviroc is not a prodrug requiring thymidine kinase activation; it is a receptor antagonist.
Option C: Option C is incorrect. UL97 is the cytomegalovirus ganciclovir-resistance gene, unrelated to maraviroc.
Option D: Option D is incorrect. Maraviroc selection is governed by tropism, not by phenotypic cross-resistance with zidovudine.
6. First-generation integrase strand transfer inhibitors (INSTIs), raltegravir and elvitegravir, are vulnerable to single signature resistance mutations. Which set of mutations corresponds to this first-generation INSTI vulnerability?
A) M184V, K65R, and the thymidine analog mutations.
B) N155H, Q148H/R/K, and Y143C/R, each of which directly alters the integrase active site.
C) K103N, Y181C, and G190A in the binding pocket.
D) rtM204V/I with the compensatory rtL180M.
E) UL97 codons 460, 594, and 595.
ANSWER: B
Rationale:
Option B is correct. First-generation INSTIs (raltegravir, elvitegravir) are defeated by single signature mutations — N155H, Q148H/R/K, and Y143C/R — that directly alter the integrase active site. Second-generation INSTIs require accumulation of two or more mutations to lose meaningful activity.
Option A: Option A is incorrect. M184V, K65R, and thymidine analog mutations are NRTI-resistance mutations in reverse transcriptase, not integrase signatures.
Option C: Option C is incorrect. K103N, Y181C, and G190A are first-generation NNRTI binding-pocket mutations, not INSTI mutations.
Option D: Option D is incorrect. rtM204V/I with rtL180M is the hepatitis B virus lamivudine-resistance pathway, not an HIV integrase signature.
Option E: Option E is incorrect. UL97 codons 460/594/595 are cytomegalovirus ganciclovir-resistance sites, unrelated to HIV integrase.
7. A clinician must choose between standard Sanger genotyping and next-generation sequencing (NGS) for a patient in whom pre-existing minority resistant variants are a concern. Which statement precisely characterizes the detection thresholds?
A) Sanger detects variants down to about 1%, while NGS detects only those above 50%.
B) Both methods detect variants down to about 1%, differing only in turnaround time.
C) Standard Sanger sequencing reliably detects variants present above approximately 15% to 20% of the population, whereas NGS can detect minority variants down to approximately 1%.
D) Sanger detects variants above 50%, while NGS detects above 15% to 20%.
E) Neither method detects variants below 35%; both are limited to majority populations.
ANSWER: C
Rationale:
Option C is correct. Conventional Sanger sequencing reliably detects mutations present in more than about 15% to 20% of the viral population, while NGS (deep sequencing) extends detection to minority variants down to roughly 1%, increasing sensitivity for pre-existing resistance that could later expand under drug pressure.
Option A: Option A is incorrect. This inverts the methods; Sanger does not reach 1%, and NGS detects well below 50%.
Option B: Option B is incorrect. The methods differ substantially in detection threshold, not merely in turnaround time.
Option D: Option D is incorrect. Sanger's threshold is about 15% to 20%, not 50%, and NGS reaches about 1%, not 15% to 20%.
Option E: Option E is incorrect. NGS detects minority variants down to about 1%, far below 35%.
8. What is a "virtual phenotype," and what advantage does it offer?
A) It uses a database of paired genotype-phenotype results to predict phenotypic susceptibility from a genotypic sequence, providing phenotype-equivalent information at genotyping turnaround time and cost.
B) It is a live cell-culture assay that measures replication across drug concentrations more rapidly than conventional phenotyping.
C) It is a host-genome test predicting drug hypersensitivity rather than viral susceptibility.
D) It is a consensus sequence assembled from multiple patients used only for population surveillance, not individual management.
E) It is a measure of plasma drug trough levels expressed as a fold-change from target.
ANSWER: A
Rationale:
Option A is correct. A virtual phenotype interprets a patient's genotypic sequence against a large database of paired genotype-phenotype results to predict phenotypic susceptibility. This yields phenotype-equivalent interpretation while preserving the faster turnaround and lower cost of genotyping.
Option B: Option B is incorrect. A virtual phenotype is a database-driven prediction, not a live cell-culture assay.
Option C: Option C is incorrect. It predicts viral drug susceptibility, not host hypersensitivity.
Option D: Option D is incorrect. It is used for individual patient interpretation, not merely a surveillance consensus sequence.
Option E: Option E is incorrect. It concerns viral susceptibility prediction, not plasma drug trough measurement.
9. Guidelines recommend HIV resistance testing at the time of diagnosis. What epidemiologic fact most directly justifies testing before any drug is ever given?
A) Transmitted resistance is essentially absent in resource-rich settings, so testing at diagnosis serves only as a documentation formality.
B) All newly diagnosed patients have wild-type virus, but baseline testing establishes a reference for later comparison.
C) Resistance mutations cannot be detected once therapy begins, so the only opportunity to test is before treatment.
D) The prevalence of transmitted resistance is approximately 10% to 15% in resource-rich settings, so a treatment-naive patient may already harbor resistance that would compromise a standard first regimen.
E) Testing at diagnosis is required because antiretroviral drugs are mutagenic and would otherwise create resistance during the first week of therapy.
ANSWER: D
Rationale:
Option D is correct. Transmitted (baseline) resistance occurs in roughly 10% to 15% of newly diagnosed patients in resource-rich settings. Because a treatment-naive patient may already carry resistance to a planned first-line agent, testing at diagnosis guides selection of an effective initial regimen.
Option A: Option A is incorrect. Transmitted resistance is not absent; its 10% to 15% prevalence is precisely why testing matters.
Option B: Option B is incorrect. Not all newly diagnosed patients have wild-type virus; transmitted resistance is the reason to test.
Option C: Option C is incorrect. Resistance can be detected on therapy (ideally on the failing regimen); the diagnosis-time rationale is transmitted resistance, not loss of detectability.
Option E: Option E is incorrect. Antiretrovirals select pre-existing variants; they are not mutagens that create resistance in the first week.
10. Entecavir has a high genetic barrier for hepatitis B virus (HBV) in treatment-naive patients, yet its barrier is substantially lower in patients with prior lamivudine resistance. What explains this difference?
A) Entecavir requires only a single mutation for resistance, and that mutation is identical to the lamivudine mutation.
B) Prior lamivudine therapy depletes hepatic entecavir-activating enzymes, reducing efficacy independent of any mutation.
C) Entecavir resistance requires three simultaneous mutations — rtM204V/I plus rtL180M plus one additional substitution; in lamivudine-resistant virus the first two are already present, so only one further mutation is needed.
D) Lamivudine resistance permanently eliminates the HBV polymerase, making any subsequent agent ineffective.
E) Entecavir and lamivudine share no resistance pathway, so prior lamivudine exposure has no mechanistic effect on entecavir.
ANSWER: C
Rationale:
Option C is correct. De novo entecavir resistance requires three simultaneous changes — rtM204V/I plus rtL180M plus one of several additional substitutions (rtI169, rtT184, rtS202, or rtM250). In a lamivudine-resistant virus, rtM204V/I and rtL180M are already present, so only one additional mutation is needed, sharply raising entecavir resistance risk and making tenofovir preferred in that setting.
Option A: Option A is incorrect. Entecavir resistance is multi-mutational, not a single mutation identical to the lamivudine change.
Option B: Option B is incorrect. The mechanism is shared pre-existing mutations, not depletion of activating enzymes.
Option D: Option D is incorrect. Lamivudine resistance does not eliminate the polymerase; it selects specific substitutions that lower the entecavir barrier.
Option E: Option E is incorrect. Entecavir and lamivudine resistance share the rtM204V/I and rtL180M pathway, which is exactly why prior exposure matters.
11. Hepatitis C virus (HCV) direct-acting antivirals are grouped by the viral protein each class targets. Which option correctly matches the three primary target classes to their functions?
A) NS3/4A is the phosphoprotein, NS5A is the polymerase, and NS5B is the protease.
B) NS3/4A is the polymerase, NS5A is the protease, and NS5B is the phosphoprotein.
C) All three classes target the same NS5B polymerase, differing only in nucleoside versus non-nucleoside chemistry.
D) NS3/4A and NS5A both target host kinases, while NS5B targets the viral envelope.
E) NS3/4A is the serine protease, NS5A is a phosphoprotein essential for replication and assembly, and NS5B is the RNA-dependent RNA polymerase (targeted by nucleoside or non-nucleoside inhibitors).
ANSWER: E
Rationale:
Option E is correct. The three primary HCV drug-target classes are NS3/4A serine protease inhibitors, NS5A phosphoprotein inhibitors, and NS5B RNA-dependent RNA polymerase inhibitors (which include both nucleoside and non-nucleoside inhibitors).
Option A: Option A is incorrect. It scrambles the assignments — NS3/4A is the protease, not the phosphoprotein, and NS5B is the polymerase, not the protease.
Option B: Option B is incorrect. This also misassigns the proteins; NS3/4A is the protease and NS5B is the polymerase.
Option C: Option C is incorrect. The three classes target three different proteins, not a single NS5B polymerase.
Option D: Option D is incorrect. These are viral protein targets, not host kinases or the envelope.
12. Although baseline resistance-associated substitution (RAS) testing is not routinely required for most treatment-naive HCV patients, NS5A RAS testing retains a defined clinical role. In which situation, and why?
A) At initial diagnosis of every patient, because NS5A substitutions block sofosbuvir activation.
B) In re-treatment planning after prior direct-acting antiviral failure, because NS5A resistance-associated substitutions can persist for years and influence regimen selection and duration.
C) Only in acute HCV, because NS5A substitutions disappear within days of infection.
D) Never, because NS5A substitutions have no measurable effect on any regimen.
E) Exclusively to confirm cure after treatment, since NS5A testing has no pretreatment role.
ANSWER: B
Rationale:
Option B is correct. NS5A resistance-associated substitutions can persist for years after exposure, unlike many other RASs that fade. This durability makes NS5A RAS testing useful when planning re-treatment after a prior NS5A-inhibitor-containing regimen has failed, guiding both regimen choice and treatment duration.
Option A: Option A is incorrect. NS5A substitutions do not block sofosbuvir (an NS5B agent), and routine testing of every naive patient is not indicated.
Option C: Option C is incorrect. NS5A substitutions persist rather than disappearing within days, and the role is in re-treatment, not acute infection.
Option D: Option D is incorrect. NS5A substitutions do affect NS5A-inhibitor-based re-treatment, so they are not without effect.
Option E: Option E is incorrect. The defined role is pretreatment re-treatment planning, not post-treatment cure confirmation.
13. In ganciclovir-resistant cytomegalovirus (CMV), the resistance consequences differ depending on whether the UL97 gene alone or the UL54 gene is mutated. Which statement about UL54 mutations is correct?
A) UL54 mutations affect only ganciclovir activation and never alter foscarnet or cidofovir activity.
B) UL54 mutations are the phosphotransferase mutations responsible for the initial step of ganciclovir resistance.
C) UL54 mutations confer resistance exclusively to maribavir.
D) UL54 (CMV DNA polymerase) mutations may produce cross-resistance to foscarnet, cidofovir, or both, depending on the specific location within the polymerase domain, and combined UL97 plus UL54 mutations are the most clinically challenging scenario.
E) UL54 mutations restore ganciclovir susceptibility lost through UL97 mutation.
ANSWER: D
Rationale:
Option D is correct. UL54 encodes the CMV DNA polymerase. Mutations there can confer cross-resistance to foscarnet, cidofovir, or both, depending on the precise domain location, because those agents act at the polymerase. Combined UL97 plus UL54 mutations represent the most difficult resistance scenario.
Option A: Option A is incorrect. UL54 mutations specifically can compromise foscarnet and/or cidofovir, the opposite of never affecting them.
Option B: Option B is incorrect. The phosphotransferase responsible for the initial ganciclovir resistance step is UL97, not UL54.
Option C: Option C is incorrect. Maribavir resistance is associated with UL97, and UL54 mutations affect polymerase-targeting agents, not maribavir exclusively.
Option E: Option E is incorrect. UL54 mutations add resistance burden; they do not restore ganciclovir susceptibility.
14. Most acyclovir-resistant herpes simplex virus (HSV) arises from thymidine kinase (TK) mutations, but a less common mechanism involves the viral DNA polymerase gene (UL30 in HSV-1). How does this less common mechanism differ in its consequences?
A) DNA polymerase (UL30) mutations confer acyclovir resistance through a TK-activation-independent route and can produce cross-resistance to foscarnet, which targets the same polymerase.
B) DNA polymerase mutations abolish viral TK, so they are simply a subset of the TK-null phenotype.
C) DNA polymerase mutations increase acyclovir susceptibility rather than conferring resistance.
D) DNA polymerase mutations affect only cidofovir while leaving acyclovir fully active.
E) DNA polymerase mutations are host mutations, so changing the antiviral agent cannot help.
ANSWER: A
Rationale:
Option A is correct. Mutations in the HSV DNA polymerase gene (UL30) confer acyclovir resistance by an activation-independent mechanism — distinct from the TK-dependent pathway — and because foscarnet also acts at the viral DNA polymerase, polymerase mutations can produce cross-resistance to foscarnet.
Option B: Option B is incorrect. Polymerase mutations are a separate mechanism from TK-null mutations, not a subset of them.
Option C: Option C is incorrect. These mutations confer resistance, not increased susceptibility.
Option D: Option D is incorrect. Polymerase mutations confer acyclovir resistance and may compromise foscarnet; they do not selectively affect only cidofovir while sparing acyclovir.
Option E: Option E is incorrect. UL30 is a viral gene; the issue is viral, and switching to a polymerase site that the mutation does not affect can still be relevant clinically.
15. Acyclovir-resistant varicella-zoster virus (VZV) is rare but recognizable. Which clinical and mechanistic description is correct?
A) It presents as classic dermatomal vesicular zoster that resolves faster than usual, driven by a polymerase mutation.
B) It occurs mainly in immunocompetent young adults and is driven by an integrase mutation.
C) It presents atypically — progressive verrucous or hyperkeratotic lesions that fail to evolve through the expected vesicular stages, often without dermatomal distribution, in immunocompromised patients — and arises through the same thymidine kinase (TK) gene mutation mechanism as acyclovir-resistant HSV; foscarnet remains active.
D) It is diagnosed by serology rather than virologic testing and responds to higher-dose acyclovir.
E) It confers automatic cross-resistance to foscarnet because TK-null strains cannot be treated by any polymerase inhibitor.
ANSWER: C
Rationale:
Option C is correct. Acyclovir-resistant VZV occurs in immunocompromised patients and presents atypically as progressive verrucous or hyperkeratotic lesions that do not pass through the usual vesicular stages and often lack a dermatomal pattern. It arises through the same TK gene mutation mechanism as acyclovir-resistant HSV, and because foscarnet does not require viral TK, TK-null VZV strains remain foscarnet-susceptible.
Option A: Option A is incorrect. Resistant VZV presents atypically and fails to heal, not as faster-resolving classic zoster.
Option B: Option B is incorrect. It occurs in immunocompromised patients and is a TK (not integrase) mechanism.
Option D: Option D is incorrect. Diagnosis relies on virologic/TK gene testing, and dose escalation does not overcome a TK defect.
Option E: Option E is incorrect. Foscarnet does not require TK and remains active against TK-null strains, so there is no automatic foscarnet cross-resistance.
16. An immunocompromised patient appears to be failing antiviral therapy. A unifying principle across herpesviruses governs the first diagnostic step. Which statement captures it?
A) True drug resistance and inadequate drug exposure present so differently that they are never confused, so empiric drug switching is always safe.
B) Antiviral failure in an immunocompromised patient should be assumed to be resistance, and therapy should be escalated empirically without any further evaluation.
C) The first step is always to increase the dose of the current agent, because pharmacokinetic failure is far more common than resistance in this population.
D) Resistance testing should be deferred until the patient becomes immunocompetent, since testing is uninformative during immunosuppression.
E) Because inadequate drug levels (poor absorption, dosing errors, interactions) and true resistance produce clinically identical pictures but require categorically different responses, drug levels and adherence should be checked first to exclude pharmacokinetic failure before attributing failure to resistance.
ANSWER: E
Rationale:
Option E is correct. Across HSV, VZV, and CMV, pharmacokinetic failure (poor absorption, dosing errors, drug interactions) and true virologic resistance can look identical clinically, yet demand different management. The unifying principle is to confirm adequate drug exposure and adherence first, then pursue virologic/resistance evaluation if pharmacokinetic failure is excluded.
Option A: Option A is incorrect. The two failure modes look clinically identical, so they are easily confused; empiric switching without assessment is not uniformly safe.
Option B: Option B is incorrect. Failure should not be assumed to be resistance without excluding pharmacokinetic causes.
Option C: Option C is incorrect. The first step is to assess drug levels and adherence, not reflexively escalate the dose.
Option D: Option D is incorrect. Resistance testing is informative during immunosuppression and should not be deferred until the patient is immunocompetent.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.